Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03443063 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03443063 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 16 participants.
The verdict
NCT03443063, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
Interventions
- DRUG Lemborexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2018-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03443063
The ClinicalTrials.gov registry entry for NCT03443063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lemborexant is the first listed.
NCT03443063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03443063 about?
NCT03443063 is a clinical study titled "Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment". This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
What is the current status of trial NCT03443063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-02-07. Estimated completion is 2018-08-24.
What interventions are being tested in trial NCT03443063?
The interventions under investigation include: Lemborexant (DRUG).
Who is sponsoring clinical trial NCT03443063?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.